STOCK TITAN

Harvard Bioscience (HBIO) Stock News, Nov 2023-May 2024

HBIO NASDAQ

Harvard Bioscience reports company news on its life science research tools business, which develops, manufactures and sells technologies, products and services for research, pharmaceutical and therapy discovery, bioproduction and preclinical testing. Updates commonly cover operating and financial results, new products for translational science, New Approach Methodologies, product mix, and customer markets that include academic institutions, government laboratories, pharmaceutical companies, biotechnology companies and contract research organizations.

Company releases also address capital actions, Nasdaq listing compliance, manufacturing and operating-model changes, management appointments, guidance, and investor conference presentations. The business sells through direct and distribution channels and has operations in the United States, Europe and China.

Rhea-AI Summary

Harvard Bioscience announced that CEO Jim Green and CFO Jennifer Cote will present at the Jefferies Global Healthcare Conference on June 5, 2024.

The event will be held at the Marriott Marquis, New York City, from 2:00 to 2:25 PM Eastern Time.

The presentation will be webcast live via the Harvard Bioscience investor relations website, with a replay available afterwards.

Additionally, the company will host one-on-one meetings with investors during the conference.

For scheduling these meetings, investors can contact healthcareconference@jefferies.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary

Harvard Bioscience announced that its CEO, Jim Green, and CFO, Jennifer Cote, will participate in the Benchmark Healthcare House Call Virtual Conference on May 22, 2024. The event will feature a live fireside chat from 9:00-9:40 am ET and one-on-one meetings with investors. Interested parties can register for the presentation or schedule meetings via the Benchmark website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
conferences
-
Rhea-AI Summary

Harvard Bioscience, Inc. (Nasdaq: HBIO) announced its first quarter 2024 financial results, reporting revenues of $24.5 million, a gross margin of 60.3%, and adjusted EBITDA of $1.6 million. Despite challenges in certain markets, the company remains focused on efficiency and growth, with a cost reduction initiative in place. The net loss for the quarter was $(4.7) million, with a decrease in revenues compared to the prior year. The company expects flat revenues for 2024, with second-half growth and a gross margin of 60%. Harvard Bioscience will be hosting a conference call to discuss the results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
Rhea-AI Summary

Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its first quarter 2024 financial results on May 7, 2024. The company will hold a conference call at 8:00 AM ET to discuss the results. Participants can register to join the call and ask questions. Financial information will be accessible on the Investor Relations section of Harvard Bioscience's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.90%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences

FAQ

What is the current stock price of Harvard Bioscience (HBIO)?

Harvard Bioscience (HBIO) last closed at $8.68.

What is the market cap of Harvard Bioscience (HBIO)?

The market cap of Harvard Bioscience (HBIO) is approximately $39.7M.